Investors

News Releases

Date Title  
Toggle Summary POZEN Inc. Licenses Compound From Roche
CHAPEL HILL, NC – November 22, 1999 – POZEN Inc. today announced that the company has acquired an exclusive worldwide license to a novel serotonin (5-HT2B) receptor antagonist discovered by F. Hoffmann-La Roche, Ltd. The compound, now known as MT 500, will be the first drug developed specifically
Toggle Summary POZEN Inc. Announces Plans to Webcast Third-Quarter Earnings Conference Call
CHAPEL HILL, N.C., Nov. 6 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of migraine products, today announced it plans to conduct a conference call following the release of financial results for the third quarter ended September 30, 2000.
Toggle Summary POZEN'S Underwriters Exercise Overallotment
CHAPEL HILL, N.C., Nov. 7 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of migraine products, today announced that the underwriters of its initial public offering have purchased an additional 750,000 shares of common stock at $15 per share pursuant
Toggle Summary POZEN Inc. Reports Third-Quarter and Nine-Month Results
CHAPEL HILL, N.C., Nov. 8 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company whose lead product candidate for the treatment of migraine is in late Phase III clinical trials, today announced results for the first time as a public company.
Toggle Summary POZEN Inc. Completes MT 100 Phase III Trials in Clinic; MT 400 Phase II Trial Begins
CHAPEL HILL, N.C., Nov. 28 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of candidates for the treatment of migraine, today announced that two late-stage Phase III clinical trials for its lead product candidate, MT 100, have been completed.
Toggle Summary POZEN, Inc. Invites You to Join Its Virtual CEO Summit Webcast
CHAPEL HILL, N.C., Dec. 5 /PRNewswire/ -- POZEN, Inc. (Nasdaq: POZN) invites you to listen to its Webcast that will be broadcast live over the Internet on Tuesday, December 5, 2000, at 1 pm ET with John Plachetka, President & CEO of POZEN, Inc. What: POZEN, Inc.Webcast When: Tuesday, December 5,
Toggle Summary POZEN Inc. Elects New Chairman
CHAPEL HILL, N.C., Jan. 16 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of product candidates for the treatment of migraine, announced that its president and chief executive officer, John R. Plachetka, Pharm.
Toggle Summary POZEN Inc. Receives FDA Request for Additional MT 100 Carcinogenicity Studies
CHAPEL HILL, N.C., Jan. 26 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of product candidates for the treatment of migraine, announced that the Food and Drug Administration (FDA) has requested additional carcinogenicity studies for MT 100, the
Toggle Summary POZEN Inc. CEO to Present at Piper Jaffray Health Care Conference
CHAPEL HILL, N.C., Jan. 31 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of product candidates for the treatment of migraine, announced that John R. Plachetka, Pharm. D., the company's chairman, president and chief executive officer, will make a
Toggle Summary POZEN'S MT 100 Meets Primary Endpoint in Final Phase III Trial
CHAPEL HILL, N.C., Feb. 21 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of product candidates for the treatment of migraine, announced that the final Phase III clinical trial for MT 100, the company's first-line treatment for migraine, has been

Copyright West LLC. Minimum 15 minutes delayed.